Catalyst Pharmaceuticals (CPRX) EPS (Basic) (2010 - 2026)

Catalyst Pharmaceuticals has reported EPS (Basic) for 17 years, with the latest figure at $0.52 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Basic) rose 10.64% year-over-year to $0.52; the trailing twelve-month figure through Mar 2026 stood at $1.81 (up 9.7% YoY), and the FY2025 full-year result was $1.75, up 26.81% from the prior year.
• EPS (Basic) for Q1 2026 stood at $0.52, up from $0.43 in the prior quarter.
• The five-year high for EPS (Basic) was $0.52 in Q1 2026, with the low at -$0.29 in Q3 2023.
• Historically, EPS (Basic) has averaged $0.3 across 5 years, with a median of $0.35 in 2024.
• Annual changes were most pronounced in 2023 — EPS (Basic) plunged 231.82% — and 2024, when it surged 227.59%.
• Catalyst Pharmaceuticals' EPS (Basic) stood at $0.24 in 2022, then surged by 37.5% to $0.33 in 2023, then soared by 39.39% to $0.46 in 2024, then slipped by 6.52% to $0.43 in 2025, then increased by 20.93% to $0.52 in 2026.
• The last three EPS (Basic) figures came in at $0.52 (Q1 2026), $0.43 (Q4 2025), and $0.43 (Q3 2025), per Business Quant data.